Navigation Links
Pharmacopeia Completes Enrollment in Phase 2 Hypertension Study with PS433540 (DARA)
Date:2/26/2008

PRINCETON, N.J., Feb. 26 /PRNewswire-FirstCall/ -- Pharmacopeia (Nasdaq: PCOP), an innovator in the discovery and development of novel small molecule therapeutics, today announced the completion of recruitment in the company's multi-center Phase 2a clinical study of PS433540 (DARA), the company's lead internal product candidate. The objective of the Phase 2a randomized, double-blind, placebo-controlled, parallel-group study is to evaluate the efficacy and safety of 200 and 500 mg of PS433540 in subjects with Stage I and Stage II hypertension.

"We have made good progress advancing DARA's clinical development. Not only did we initiate this Phase 2a study approximately six months ahead of our original clinical development timeline, but we have now completed enrollment in the study with the expectation of reporting results in the second quarter of 2008," said Les Browne, Ph.D., Pharmacopeia's President and Chief Executive Officer. "As this is the first PS433540 study to include hypertensive patients, we are pleased to have the opportunity to demonstrate that DARA can effectively lower blood pressure in this patient population."

Results from Phase 1 studies of PS433540 in normal subjects have indicated that the compound was well tolerated at all doses up to and including 1,000 mg a day for 14 days. Several studies including the multiple ascending dose (MAD) and angiotensin II challenge studies have shown that PS433540 appears to have a pharmacokinetic profile consistent with once-daily oral administration. In the angiotensin challenge study, 250 and 500 mg of PS433540 fully blocked the increase in blood pressure induced by administration of angiotensin II (AII) to healthy volunteers at least as well as 300 mg of irbesartan, the t
'/>"/>

SOURCE Pharmacopeia
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
2. Pharmacopeia Announces Positive Results from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
3. Pharmacopeia Initiates Phase 2 Hypertension Study with PS433540 (DARA)
4. Phase 2 Clinical Studies Initiated for a Novel Therapeutic Candidate Identified Through Pharmacopeia Collaboration
5. Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate
6. Pharmacopeia Announces Third Quarter 2007 Financial Results
7. Pharmacopeia Announces Additional Positive Findings from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
8. Pharmacopeia to Present at BIO CEO & Investor Conference 2008
9. Pharmacopeia Nominates Novel Chemokine Receptor Antagonist for Development
10. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
11. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... , May 5, 2015  Omron Healthcare, Inc., the ... of a new blood pressure monitor and scale with connectivity ... telehealth applications. ... care on the rise, remote patient monitoring has become increasingly ... cost savings. ...
(Date:5/5/2015)... NORTHBROOK, Ill. , May 5, 2015  Astellas ... of enzalutamide and one abstract detailing clinical data from ... solifenacin will be presented during a late breaking plenary ... Urological Association (AUA) on May 17 in ... data from two Phase 2 studies designed to evaluate ...
(Date:5/5/2015)... 2015 Omeros Corporation (NASDAQ: OMER ... and commercializing both small-molecule and protein therapeutics for ... coagulopathies and disorders of the central nervous system, ... first quarter 2015 financial results for the period ... 2015, after market close. Omeros management will host ...
Breaking Medicine Technology:New Blood Pressure Monitor And Scale Allow Chronically Ill Patients To Stay At Home While Connected To Healthcare Professionals 2New Blood Pressure Monitor And Scale Allow Chronically Ill Patients To Stay At Home While Connected To Healthcare Professionals 3Astellas Announces New Data To Be Presented During Late Breaking Plenary Session At AUA Annual Meeting 2Astellas Announces New Data To Be Presented During Late Breaking Plenary Session At AUA Annual Meeting 3Astellas Announces New Data To Be Presented During Late Breaking Plenary Session At AUA Annual Meeting 4Astellas Announces New Data To Be Presented During Late Breaking Plenary Session At AUA Annual Meeting 5Astellas Announces New Data To Be Presented During Late Breaking Plenary Session At AUA Annual Meeting 6Astellas Announces New Data To Be Presented During Late Breaking Plenary Session At AUA Annual Meeting 7Astellas Announces New Data To Be Presented During Late Breaking Plenary Session At AUA Annual Meeting 8Astellas Announces New Data To Be Presented During Late Breaking Plenary Session At AUA Annual Meeting 9Omeros Corporation to Announce First Quarter 2015 Financial Results on May 11, 2015 2
... Boston Scientific Corporation (NYSE: BSX ) announces ... be presented at Digestive Disease Week ® (DDW), ... involve the SpyGlass ® Direct Visualization System, WallFlex® ... Needle and Resolution® Clip. "The volume and ...
... Pharmaceuticals, Inc. (NYSE: WPI ) today ... an Abbreviated New Drug Application (ANDA) with the ... to market Norethindrone Acetate/Ethinyl Estradiol and Ethinyl Estradiol and ... 75 mg. Watson,s ANDA product is a generic ...
Cached Medicine Technology:Boston Scientific Endoscopy Presents Promising Clinical Data During Digestive Disease Week ® 2Boston Scientific Endoscopy Presents Promising Clinical Data During Digestive Disease Week ® 3Boston Scientific Endoscopy Presents Promising Clinical Data During Digestive Disease Week ® 4Boston Scientific Endoscopy Presents Promising Clinical Data During Digestive Disease Week ® 5Watson Confirms Lo Loestrin® Fe Patent Challenge 2Watson Confirms Lo Loestrin® Fe Patent Challenge 3
(Date:5/5/2015)... Soledad, CA (PRWEB) May 05, 2015 ... just ahead, Josie's Organics, one of the country's ... through the minds of moms across the country. ... through the family recipe box or spend hours ... recipes today on http://www.josiesorganics.com/recipes . , ...
(Date:5/5/2015)... What do you get when you combine one of ... and one of the world’s greatest causes? The world’s greatest ... Marc Middleton, which follows world-renowned mountaineer Chris Warner as he ... summit of Mount Kilimanjaro. , “This film is designed ... Viewers are moved to ask, ‘What can I do?’” said ...
(Date:5/5/2015)... AR (PRWEB) May 05, 2015 ... is collaborating with American Eagle Outfitters on a ... enhance natural beauty. , For the debut ... with Aerie by American Eagle ; the ... brand's body-image campaign, called "Aerie REAL," uses models ...
(Date:5/5/2015)... NovaSom, Inc., announced today that they will ... Ed Begley Jr., airing via Discovery Channel 3rd QTR ... will focus on NovaSom, a leader in Obstructive Sleep ... AccuSom® home sleep test, which is the only comprehensively ... and next-day test results and interpretation. , ...
(Date:5/5/2015)... Crawford Technologies announced today it has been awarded a ... of the Business Marketing Association (BMA) for the redesign of ... presented to the CrawfordTech marketing team on Friday, May 1, ... 300 people in attendance. , “The launch of the new ... shift in focus for how our company communicates our value ...
Breaking Medicine News(10 mins):Health News:Josie's Organics Kicks Off Mother's Day, Graduation and Grilling Season with New, Easy-to-Follow, Convenient Recipes 2Health News:Josie's Organics Kicks Off Mother's Day, Graduation and Grilling Season with New, Easy-to-Follow, Convenient Recipes 3Health News:Josie's Organics Kicks Off Mother's Day, Graduation and Grilling Season with New, Easy-to-Follow, Convenient Recipes 4Health News:LIVESTRONG & Bolder Broadcasting Present Special Edition of Conquering Kilimanjaro 2Health News:LIVESTRONG & Bolder Broadcasting Present Special Edition of Conquering Kilimanjaro 3Health News:BLKBOXLabs Finds Real Beauty in Beauty For Real and American Eagle Outfitters’ Aerie-Branded Beauty Line 2Health News:BLKBOXLabs Finds Real Beauty in Beauty For Real and American Eagle Outfitters’ Aerie-Branded Beauty Line 3Health News:Innovations with Ed Begley, Jr. to Explore NovaSom, Inc., in Upcoming Episode 2Health News:Crawford Technologies Awarded BMA’s ‘2015 Gold Key Award’ for Innovative Website Redesign 2Health News:Crawford Technologies Awarded BMA’s ‘2015 Gold Key Award’ for Innovative Website Redesign 3
... are reluctant to disclose identifiable patient information, even in ... effort to protect patient privacy. A recently published study ... in Electronic Health Information at the University of Ottawa ... recently found that during the peak of the H1N1 ...
... DIEGO, CA A smaller sized hamstring graft in ... years old may increase revision rates, according to research presented ... in San Diego today. "Hamstring grafts are commonly ... the average being 8mm in diameter. Our research illustrated that ...
... with blood clots -- which occur in one of every ... of death among cancer patients -- gain no benefit from ... the anticoagulant medication fondaparinux (Arixtra), according to research presented today ... the International Association for the Study of Lung Cancer. ...
... in full swing in Germany, soccer fans can now rest ... on-field injuries, according to a new study by researchers at ... of the journal Research in Sports Medicine. , "Injuries ... the rise at the international level," said Daryl Rosenbaum, M.D., ...
... HealthDay Reporter , WEDNESDAY, July 6 (HealthDay ... work may suffer from debilitating fatigue that could hamper ... combat this problem, the U.S. Federal Aviation Administration should ... a safety risk, according to the report from the ...
... new study published in The Journal of Sexual ... as weight problems, physical inactivity, high alcohol consumption, tobacco ... in men. Additionally, an unhealthy lifestyle is more common ... Associate Professor Morten Frisch, MD, PhD, DSc, of Statens ...
Cached Medicine News:Health News:New report explains why physicians are reluctant to share patient data 2Health News:New study: Women less likely than men to fake soccer injuries 2Health News:Long Commutes for Pilots May Hamper Flying Performance: Study 2Health News:Long Commutes for Pilots May Hamper Flying Performance: Study 3Health News:Long Commutes for Pilots May Hamper Flying Performance: Study 4Health News:An unhealthy lifestyle is associated with sexual dysfunction 2
... leg bags are part of the ... line of leg bags, kits, and ... needs of our customers. These leg ... and constructed of 100% latex-free soft, ...
... bags are part of the Freedom ... of leg bags, kits, and accessories ... of our customers. These leg bags ... constructed of 100% latex-free soft, textured ...
The latex-free, PVC-free Antibacterial Hydro Personal catheter combines two remarkable innovations into one exclusive catheter that delivers an antibacterial agent while providing the virtually frict...
The latex-free, PVC-free Antibacterial Hydro Personal catheter combines two remarkable innovations into one exclusive catheter that delivers an antibacterial agent while providing the virtually frict...
Medicine Products: